Equiplas-E is specifically designed to prevent Endotoxaemia in horses, a potentially fatal condition.

Equiplas-E is Plasvacc's equine plasma product specifically designed to prevent Enterotoxaemia in horses. Rich in specific anti-edotoxin gamma globulins, Equiplas-E is collected from specially hyperimmunised donor horses that reside at the Plasvacc plasma production facility, the only facility of its kind in Australia.

Enterotoxaemia (ETA), or Colitis X as it is otherwise known, is a condition whereby bacteria in the process of dying release a protein that is toxic to the host animal. Because it is the toxin that is harmful, rather than the organism itself, which would be susceptible to antibiotics, treatmento f this condition is not straightforward. The administration of targeted antibodies is the only specific method of treatment for this condition and such antibodies are contained in Plasvacc's Equiplas-E product.

The development of Equiplas-E represents a significant improvement in the treatment modalities for this condition. Equiplas-E does not replace all present conventional treatments of ETA, rather it complements these treatments and shortens the course of hospitalisation, thereby saving animals that may not normally survive.

Equiplas-E is yet to be registered with the Ausralian Pesticide and Veterinary Medicines Authority.